New investigations found that tumor with sarcomatoid variant may express higher percentage PD-1/PD-L1 than those without sarcomatoid variant, suggesting that tumor with sarcomatoid variant may be more suitable for anti-PD-1/PD-L1 therapy [27]. The gene discussed is CD274; the disease is neoplasm.